Associate Professor of Internal Medicine
[email protected]
Available to mentor
Geoffrey D Barnes, MD, MSc
Associate Professor
Dr. Barnes is a cardiologist and vascular medicine specialist. His research focuses on developing, implementing, and evaluating antithrombotic stewardship efforts to improve the care of patients with thrombotic conditions and/or those who use anticoagulant medications. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and as co-director for the Michigan Program on Value Enhancement (MPrOVE). His research is funded by the NIH, AHRQ, and Blue Cross-Blue Shield of Michigan. He serves in leadership roles with several national and International organizations, including the Anticoagulation Forum, American College of Cardiology, and International Society on Thrombosis and Hemostasis. He also serves as the program director for the University of Michigan Vascular Medicine fellowship training program.
-
Cardiovascular Medicine FellowshipUniversity of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
-
Vascular Medicine FellowshipUniversity of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
-
Internal Medicine Chief ResidencyUniversity of Michigan, Internal Medicine, 2011
-
Internal Medicine ResidencyUniversity of Michigan, Internal Medicine, 2010
-
MSUniversity of Michigan, Ann Arbor, 2015
-
MDUniversity of Michigan, 1500 E. Medical Center Drive, 2007
-
BSWashington University in St. Louis, St. Louis, 2003
-
Center MemberPrecision Health Initiative
-
Center MemberCenter for Bioethics and Social Sciences in Medicine
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
Anticoagulation therapy
Venous Thromboembolism
Implementation Science
Quality Improvement
Health systems engineering
Shared decision-making
-
Kurlander JE, Mafi JN, Racz MJ, Barnes GD, Saini SD, Meek PD, Gastrointestinal Bleeding Working Group . Clin Gastroenterol Hepatol, 2024 Feb 15;Journal ArticlePrescribing of Proton Pump Inhibitors for Prevention of Upper Gastrointestinal Bleeding in US Outpatient Visits.
DOI:10.1016/j.cgh.2024.01.047 PMID: 38367740 -
Schaefer JK, Barnes GD. Thromb Haemost, 2024 Aug; 124 (8): 791 - 794.Journal ArticleAre the Direct Oral Anticoagulants Better for Patients with Low Time in the Therapeutic Range on Vitamin K Antagonist Therapy?
DOI:10.1055/s-0044-1787299 PMID: 38823378 -
Talasaz AH, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom JW, Siegal DM, Monreal M, Jimenez D, Vaduganathan M, Castellucci LA, Cuker A, Barnes GD, Connors JM, Secemsky EA, Van Tassell BW, De Caterina R, Kurlander JE, Aminian A, Piazza G, Goldhaber SZ, Moores L, Middeldorp S, Kirtane AJ, Elkind MSV, Angiolillo DJ, Konstantinides S, Lip GYH, Stone GW, Cushman M, Krumholz HM, Mehran R, Bhatt DL, Bikdeli B. Nat Rev Cardiol, 2024 Aug; 21 (8): 574 - 592.Journal ArticleOptimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease.
DOI:10.1038/s41569-024-01003-3 PMID: 38509244 -
Herron GC, DeCamillo D, Kong X, Haymart B, Kaatz S, Ellsworth S, Ali MA, Giuliano C, Froehlich JB, Barnes GD. Thromb Haemost, 2024 Jul 30;Journal ArticleTiming of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems.
DOI:10.1055/a-2365-8681 PMID: 39009007 -
Ward C, Curry N, El-Ekiaby M, Jurk K, Versteeg HH, Keragala C, Burstyn-Cohen T, Antoniak S, Suzuki Y, Baker RI, Christophe O, Revel-Vilk S, Hart A, Deppermann C, Tran H, Pozzi N, Kahr WHA, Grover SP, Wenzel P, Brown AC, Oury C, Shea SM, Fredenburgh J, Passam FH, Winearls J, Moore HB, Tole S, Merriman E, Barnes GD, Leonardo Liu Z, Sholzberg M, Rivera J, Marín-Quilez A. Research and Practice in Thrombosis and Haemostasis, 2024 Jul 1; 8 (5):Journal ArticleErratum to ‘Illustrated State-of-the-Art Capsules of the ISTH 2024 Congress’ [Research and Practice in Thrombosis and Haemostasis Volume 8, Issue 4, May 2024, 102432](S2475037924001213)(10.1016/j.rpth.2024.102432)
DOI:10.1016/j.rpth.2024.102498 -
Goodman SG, Roy D, Pollack CV, Leblanc K, Kwaku KF, Barnes GD, Bonaca MP, True Hills M, Campello E, Fanikos J, Connors JM, Weitz JI. Crit Pathw Cardiol, 2024 Jun 1; 23 (2): 47 - 57.Journal ArticleCurrent Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics.
DOI:10.1097/HPC.0000000000000351 PMID: 38381695 -
Mukerjee R, Hirschtick JL, Arciniega LZ, Xie Y, Barnes GD, Arenberg DA, Levy DT, Meza R, Fleischer NL, Cook SF. Am J Prev Med, 2024 May; 66 (5): 789 - 796.Journal ArticleENDS, Cigarettes, and Respiratory Illness: Longitudinal Associations Among U.S. Youth.
DOI:10.1016/j.amepre.2023.12.005 PMID: 38081374 -
Haymart B, Kong X, Ali M, Schaefer JK, Froehlich JB, Ryan N, Stallings B, Barnes GD, Kaatz S. Am J Med, 2024 May; 137 (5): 449 - 453.Journal ArticlePrevalence of Guideline-Discordant Aspirin Use and Associated Adverse Events in Patients on Warfarin for Mechanical Valve Replacement.
DOI:10.1016/j.amjmed.2024.01.015 PMID: 38280559
Health Lab
More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. These DOACs, such as rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), are under- or over-prescribed in up to one in eight patents. These prescribing issues can have life-threatening consequences, and they most often occur after a provider writes the initial prescription, according to a study led by Michigan Medicine.
Research News
Dr. Geoff Barne's named on the 2024 Top LGBTQ+ Doctors List
